We showed that a GSK3β inhibitor selectively inhibited FHIT-deficient lung cancer by inhibiting the ATR/BRCA1/RAD51 signaling axis and BRCA1/RAD51 transcription, leading to the inhibition of HRR and genotoxic cell death. This evidence concerns the gene GSK3B and lung carcinoma.